NCT05254899 2022-02-24Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTLChineseAMSPhase 2 Unknown54 enrolled
NCT04620837 2020-11-09Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line ChemotherapyChineseAMSPhase 2 Unknown25 enrolled